ÌÇÐÄvlog

Object moved to here.

Updates on Acute Coronary Syndrome: A Review | Emergency Medicine | JAMA Cardiology | ÌÇÐÄvlog

ÌÇÐÄvlog

[Skip to Navigation]
Sign In
1.
Roth ÌýGA, Huffman ÌýMD, Moran ÌýAE, Ìýet al. ÌýGlobal and regional patterns in cardiovascular mortality from 1990 to 2013.ÌýÌý°ä¾±°ù³¦³Ü±ô²¹³Ù¾±´Ç²Ô. 2015;132(17):1667-1678.
2.
Gupta ÌýA, Wang ÌýY, Spertus ÌýJA, Ìýet al. ÌýTrends in acute myocardial infarction in young patients and differences by sex and race, 2001 to 2010.ÌýÌýJ Am Coll Cardiol. 2014;64(4):337-345.
3.
Libby ÌýP, Pasterkamp ÌýG. ÌýRequiem for the “vulnerable plaque.Ìý†ÌýEur Heart J. 2015;36(43):2984-2987.
4.
Jia ÌýH, Abtahian ÌýF, Aguirre ÌýAD, Ìýet al. ÌýIn vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography.ÌýÌýJ Am Coll Cardiol. 2013;62(19):1748-1758.
5.
Higuma ÌýT, Soeda ÌýT, Abe ÌýN, Ìýet al. ÌýA combined optical coherence tomography and intravascular ultrasound study on plaque rupture, plaque erosion, and calcified nodule in patients with ST-segment elevation myocardial infarction: incidence, morphologic characteristics, and outcomes after percutaneous coronary intervention.ÌýÌýJACC Cardiovasc Interv. 2015;8(9):1166-1176.
6.
Deftereos ÌýS, Giannopoulos ÌýG, Angelidis ÌýC, Ìýet al. ÌýAnti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study.ÌýÌý°ä¾±°ù³¦³Ü±ô²¹³Ù¾±´Ç²Ô. 2015;132(15):1395-1403.
7.
Cung ÌýTT, Morel ÌýO, Cayla ÌýG, Ìýet al. ÌýCyclosporine before PCI in patients with acute myocardial infarction.ÌýÌýN Engl J Med. 2015;373(11):1021-1031.
8.
Eitel ÌýI, Stiermaier ÌýT, Rommel ÌýKP, Ìýet al. ÌýCardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial.ÌýÌýEur Heart J. 2015;36(44):3049-3057.
9.
Han ÌýY, Guo ÌýJ, Zheng ÌýY, Ìýet al; BRIGHT Investigators. ÌýBivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.ÌýÌý´³´¡²Ñ´¡. 2015;313(13):1336-1346.
10.
Bhatt ÌýDL, Stone ÌýGW, Mahaffey ÌýKW, Ìýet al; CHAMPION PHOENIX Investigators. ÌýEffect of platelet inhibition with cangrelor during PCI on ischemic events.ÌýÌýN Engl J Med. 2013;368(14):1303-1313.
11.
clinicaltrials.gov. Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD. NCT01399736. . Accessed June 14, 2016.
12.
clinicaltrials.gov. Complete vs Culprit-Only Revascularization to Treat Multi-vessel Disease After Primary PCI for STEMI. NCT01740479. . Accessed June 14, 2016.
13.
Gershlick ÌýAH, Khan ÌýJN, Kelly ÌýDJ, Ìýet al. ÌýRandomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial.ÌýÌýJ Am Coll Cardiol. 2015;65(10):963-972.
14.
Engstrøm ÌýT, Kelbæk ÌýH, Helqvist ÌýS, Ìýet al; DANAMI-3–PRIMULTI Investigators. ÌýComplete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3–PRIMULTI): an open-label, randomised controlled trial.ÌýÌý³¢²¹²Ô³¦±ð³Ù. 2015;386(9994):665-671.
15.
Mauri ÌýL, Kereiakes ÌýDJ, Yeh ÌýRW, Ìýet al; DAPT Study Investigators. ÌýTwelve or 30 months of dual antiplatelet therapy after drug-eluting stents.ÌýÌýN Engl J Med. 2014;371(23):2155-2166.
16.
Yeh ÌýRW, Kereiakes ÌýDJ, Steg ÌýPG, Ìýet al; DAPT Study Investigators. ÌýBenefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction.ÌýÌýJ Am Coll Cardiol. 2015;65(20):2211-2221.
17.
Steg ÌýPG, van’t Hof ÌýA, Hamm ÌýCW, Ìýet al; EUROMAX Investigators. ÌýBivalirudin started during emergency transport for primary PCI.ÌýÌýN Engl J Med. 2013;369(23):2207-2217.
18.
Shahzad ÌýA, Kemp ÌýI, Mars ÌýC, Ìýet al; HEAT-PPCI Trial Investigators. ÌýUnfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial [published correction appears in Lancet. 2014;384(9957):1848].ÌýÌý³¢²¹²Ô³¦±ð³Ù. 2014;384(9957):1849-1858.
19.
Cannon ÌýCP, Blazing ÌýMA, Giugliano ÌýRP, Ìýet al; IMPROVE-IT Investigators. ÌýEzetimibe added to statin therapy after acute coronary syndromes.ÌýÌýN Engl J Med. 2015;372(25):2387-2397.
20.
Murphy ÌýSA, Cannon ÌýCP, Blazing ÌýMA, Ìýet al. ÌýReduction in total cardiovascular events with ezetimibe/simvastatin post–acute coronary syndrome: the IMPROVE-IT trial.ÌýÌýJ Am Coll Cardiol. 2016;67(4):353-361.
21.
Valgimigli ÌýM, Frigoli ÌýE, Leonardi ÌýS, Ìýet al; MATRIX Investigators. ÌýBivalirudin or unfractionated heparin in acute coronary syndromes.ÌýÌýN Engl J Med. 2015;373(11):997-1009.
22.
Valgimigli ÌýM, Gagnor ÌýA, Calabró ÌýP, Ìýet al; MATRIX Investigators. ÌýRadial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial.ÌýÌý³¢²¹²Ô³¦±ð³Ù. 2015;385(9986):2465-2476.
23.
O’Malley ÌýRG, Bonaca ÌýMP, Scirica ÌýBM, Ìýet al. ÌýPrognostic performance of multiple biomarkers in patients with non–ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndromes–Thrombolysis in Myocardial Infarction 36).ÌýÌýJ Am Coll Cardiol. 2014;63(16):1644-1653.
24.
Ibanez ÌýB, Macaya ÌýC, Sánchez-Brunete ÌýV, Ìýet al. ÌýEffect of early metoprolol on infarct size in ST-segment–elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial.ÌýÌý°ä¾±°ù³¦³Ü±ô²¹³Ù¾±´Ç²Ô. 2013;128(14):1495-1503.
25.
Mateos ÌýA, García-Lunar ÌýI, García-Ruiz ÌýJM, Ìýet al; METOCARD-CNIC Investigators. ÌýEfficacy and safety of out-of-hospital intravenous metoprolol administration in anterior ST-segment elevation acute myocardial infarction: insights from the METOCARD-CNIC trial.ÌýÌýAnn Emerg Med. 2015;65(3):318-324.
26.
Pizarro ÌýG, Fernández-Friera ÌýL, Fuster ÌýV, Ìýet al. ÌýLong-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction).ÌýÌýJ Am Coll Cardiol. 2014;63(22):2356-2362.
27.
Robinson ÌýJG, Farnier ÌýM, Krempf ÌýM, Ìýet al; ODYSSEY LONG TERM Investigators. ÌýEfficacy and safety of alirocumab in reducing lipids and cardiovascular events.ÌýÌýN Engl J Med. 2015;372(16):1489-1499.
28.
Sabatine ÌýMS, Giugliano ÌýRP, Wiviott ÌýSD, Ìýet al; Open-Label Study of Long-Term Evaluation Against LDL Cholesterol (OSLER) Investigators. ÌýEfficacy and safety of evolocumab in reducing lipids and cardiovascular events.ÌýÌýN Engl J Med. 2015;372(16):1500-1509.
29.
McMurray ÌýJJ, Packer ÌýM, Desai ÌýAS, Ìýet al; PARADIGM-HF Investigators and Committees. ÌýAngiotensin–neprilysin inhibition versus enalapril in heart failure.ÌýÌýN Engl J Med. 2014;371(11):993-1004.
30.
Bonaca ÌýMP, Bhatt ÌýDL, Cohen ÌýM, Ìýet al; PEGASUS-TIMI 54 Steering Committee and Investigators. ÌýLong-term use of ticagrelor in patients with prior myocardial infarction.ÌýÌýN Engl J Med. 2015;372(19):1791-1800.
31.
Wald ÌýDS, Morris ÌýJK, Wald ÌýNJ, Ìýet al; PRAMI Investigators. ÌýRandomized trial of Preventive Angioplasty in Myocardial Infarction.ÌýÌýN Engl J Med. 2013;369(12):1115-1123.
32.
Leoncini ÌýM, Toso ÌýA, Maioli ÌýM, Tropeano ÌýF, Villani ÌýS, Bellandi ÌýF. ÌýEarly high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Acute Kidney Injury and Myocardial Damage in Patients With Acute Coronary Syndrome).ÌýÌýJ Am Coll Cardiol. 2014;63(1):71-79.
33.
Milosevic ÌýA, Vasiljevic-Pokrajcic ÌýZ, Milasinovic ÌýD, Ìýet al. ÌýImmediate versus delayed invasive intervention for non-STEMI patients: the RIDDLE-NSTEMI study.ÌýÌýJACC Cardiovasc Interv. 2016;9(6):541-549.
34.
SCOT-HEART Investigators. ÌýCT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial.ÌýÌý³¢²¹²Ô³¦±ð³Ù. 2015;385(9985):2383-2391.
35.
Fröbert ÌýO, Lagerqvist ÌýB, Olivecrona ÌýGK, Ìýet al; TASTE Trial. ÌýThrombus aspiration during ST-segment elevation myocardial infarction [published correction appears in N Engl J Med. 2014;371(8):786].ÌýÌýN Engl J Med. 2013;369(17):1587-1597.
36.
Lagerqvist ÌýB, Fröbert ÌýO, Olivecrona ÌýGK, Ìýet al. ÌýOutcomes 1 year after thrombus aspiration for myocardial infarction.ÌýÌýN Engl J Med. 2014;371(12):1111-1120.
37.
Jolly ÌýSS, Cairns ÌýJA, Yusuf ÌýS, Ìýet al; TOTAL Investigators. ÌýRandomized trial of primary PCI with or without routine manual thrombectomy.ÌýÌýN Engl J Med. 2015;372(15):1389-1398.
38.
Jolly ÌýSS, Cairns ÌýJA, Yusuf ÌýS, Ìýet al; TOTAL Investigators. ÌýOutcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial.ÌýÌý³¢²¹²Ô³¦±ð³Ù. 2016;387(10014):127-135.
39.
Amin ÌýAP, Wang ÌýTY, McCoy ÌýL, Ìýet al. ÌýImpact of bleeding on quality of life in patients on DAPT: insights from TRANSLATE-ACS.ÌýÌýJ Am Coll Cardiol. 2016;67(1):59-65.
40.
Jackson ÌýLR ÌýII, Ju ÌýC, Zettler ÌýM, Ìýet al. ÌýOutcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study.ÌýÌýJACC Cardiovasc Interv. 2015;8(14):1880-1889.
41.
Dewilde ÌýWJ, Oirbans ÌýT, Verheugt ÌýFW, Ìýet al; WOEST Study Investigators. ÌýUse of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.ÌýÌý³¢²¹²Ô³¦±ð³Ù. 2013;381(9872):1107-1115.
42.
Melki ÌýD, LugnegÃ¥rd ÌýJ, Alfredsson ÌýJ, Ìýet al. ÌýImplications of introducing high-sensitivity cardiac troponin T into clinical practice: data from the SWEDEHEART Registry.ÌýÌýJ Am Coll Cardiol. 2015;65(16):1655-1664.
43.
Bandstein ÌýN, Ljung ÌýR, Johansson ÌýM, Holzmann ÌýMJ. ÌýUndetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction.ÌýÌýJ Am Coll Cardiol. 2014;63(23):2569-2578.
44.
Cullen ÌýL, Mueller ÌýC, Parsonage ÌýWA, Ìýet al. ÌýValidation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome.ÌýÌýJ Am Coll Cardiol. 2013;62(14):1242-1249.
45.
Shah ÌýAS, Anand ÌýA, Sandoval ÌýY, Ìýet al; High-STEACS Investigators. ÌýHigh-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study.ÌýÌý³¢²¹²Ô³¦±ð³Ù. 2015;386(10012):2481-2488.
46.
Moussa ÌýID, Klein ÌýLW, Shah ÌýB, Ìýet al. ÌýConsideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI).ÌýÌýJ Am Coll Cardiol. 2013;62(17):1563-1570.
47.
Hicks ÌýKA, Tcheng ÌýJE, Bozkurt ÌýB, Ìýet al. Ìý2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards) [published correction appears in J Am Coll Cardiol. 2015;66(8):982].ÌýÌýJ Am Coll Cardiol. 2015;66(4):403-469.
48.
Rybicki ÌýFJ, Udelson ÌýJE, Peacock ÌýWF, Ìýet al. Ìý2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS appropriate utilization of cardiovascular imaging in emergency department patients with chest pain: a joint document of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Appropriate Use Criteria Task Force.ÌýÌýJ Am Coll Cardiol. 2016;67(7):853-879.
49.
Dedic ÌýA, Lubbers ÌýMM, Schaap ÌýJ, Ìýet al. ÌýCoronary CT angiography for suspected ACS in the era of high-sensitivity troponins: randomized multicenter study.ÌýÌýJ Am Coll Cardiol. 2016;67(1):16-26.
50.
Ferencik ÌýM, Hoffmann ÌýU, Bamberg ÌýF, Januzzi ÌýJL. ÌýHighly sensitive troponin and coronary computed tomography angiography in the evaluation of suspected acute coronary syndrome in the emergency department [published online February 2, 2016].ÌýÌýEur Heart J.
51.
Joshi ÌýNV, Vesey ÌýAT, Williams ÌýMC, Ìýet al. Ìý18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial.ÌýÌý³¢²¹²Ô³¦±ð³Ù. 2014;383(9918):705-713.
52.
Noguchi ÌýT, Kawasaki ÌýT, Tanaka ÌýA, Ìýet al. ÌýHigh-intensity signals in coronary plaques on noncontrast T1-weighted magnetic resonance imaging as a novel determinant of coronary events.ÌýÌýJ Am Coll Cardiol. 2014;63(10):989-999.
53.
Madder ÌýRD, Husaini ÌýM, Davis ÌýAT, Ìýet al. ÌýLarge lipid-rich coronary plaques detected by near-infrared spectroscopy at non-stented sites in the target artery identify patients likely to experience future major adverse cardiovascular events.ÌýÌýEur Heart J Cardiovasc Imaging. 2016;17(4):393-399.
54.
Yeh ÌýRW, Secemsky ÌýEA, Kereiakes ÌýDJ, Ìýet al; DAPT Study Investigators. ÌýDevelopment and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention.ÌýÌý´³´¡²Ñ´¡. 2016;315(16):1735-1749.
55.
Généreux ÌýP, Giustino ÌýG, Witzenbichler ÌýB, Ìýet al. ÌýIncidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention.ÌýÌýJ Am Coll Cardiol. 2015;66(9):1036-1045.
56.
Udell ÌýJA, Bonaca ÌýMP, Collet ÌýJP, Ìýet al. ÌýLong-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.ÌýÌýEur Heart J. 2016;37(4):390-399.
57.
Tantry ÌýUS, Bonello ÌýL, Aradi ÌýD, Ìýet al; Working Group on On-Treatment Platelet Reactivity. ÌýConsensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.ÌýÌýJ Am Coll Cardiol. 2013;62(24):2261-2273.
58.
Kirtane ÌýAJ, Parikh ÌýPB, Stuckey ÌýTD, Ìýet al. ÌýIs there an ideal level of platelet P2Y12-receptor inhibition in patients undergoing percutaneous coronary intervention? “window†analysis from the ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).ÌýÌýJACC Cardiovasc Interv. 2015;8(15):1978-1987.
59.
Cavender ÌýMA, Sabatine ÌýMS. ÌýBivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.ÌýÌý³¢²¹²Ô³¦±ð³Ù. 2014;384(9943):599-606.
60.
Kikkert ÌýWJ, van Geloven ÌýN, van der Laan ÌýMH, Ìýet al. ÌýThe prognostic value of Bleeding Academic Research Consortium (BARC)–defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis in Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications.ÌýÌýJ Am Coll Cardiol. 2014;63(18):1866-1875.
61.
Hess ÌýCN, Peterson ÌýED, Peng ÌýSA, Ìýet al. ÌýUse and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation.ÌýÌýJ Am Coll Cardiol. 2015;66(6):616-627.
62.
Amsterdam ÌýEA, Wenger ÌýNK, Brindis ÌýRG, Ìýet al; ACC/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Ìý2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014;130(25):e431-e432.].ÌýÌý°ä¾±°ù³¦³Ü±ô²¹³Ù¾±´Ç²Ô. 2014;130(25):2354-2394.
63.
Roffi ÌýM, Patrono ÌýC, Collet ÌýJP, Ìýet al. Ìý2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).ÌýÌýEur Heart J. 2016;37(3):267-315.
64.
Levine ÌýGN, Bates ÌýER, Blankenship ÌýJC, Ìýet al. Ìý2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction.ÌýÌýJ Am Coll Cardiol. 2016;67(10):1235-1250.
65.
Menees ÌýDS, Peterson ÌýED, Wang ÌýY, Ìýet al. ÌýDoor-to-balloon time and mortality among patients undergoing primary PCI.ÌýÌýN Engl J Med. 2013;369(10):901-909.
66.
Nallamothu ÌýBK, Normand ÌýSL, Wang ÌýY, Ìýet al. ÌýRelation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study.ÌýÌý³¢²¹²Ô³¦±ð³Ù. 2015;385(9973):1114-1122.
67.
Giugliano ÌýRP, Sabatine ÌýMS. ÌýAre PCSK9 inhibitors the next breakthrough in the cardiovascular field?ÌýÌýJ Am Coll Cardiol. 2015;65(24):2638-2651.
68.
Kubica ÌýJ, Adamski ÌýP, Ostrowska ÌýM, Ìýet al. ÌýMorphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.ÌýÌýEur Heart J. 2016;37(3):245-252.
69.
Puymirat ÌýE, Lamhaut ÌýL, Bonnet ÌýN, Ìýet al. ÌýCorrelates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-Elevation and Non–ST-Elevation Myocardial Infarction) programme.ÌýÌýEur Heart J. 2016;37(13):1063-1071.
70.
Pokorney ÌýSD, Miller ÌýAL, Chen ÌýAY, Ìýet al. ÌýImplantable cardioverter-defibrillator use among Medicare patients with low ejection fraction after acute myocardial infarction.ÌýÌý´³´¡²Ñ´¡. 2015;313(24):2433-2440.
71.
Hess ÌýPL, Wojdyla ÌýDM, Al-Khatib ÌýSM, Ìýet al. ÌýSudden cardiac death after non–ST-segment elevation acute coronary syndrome.ÌýÌý´³´¡²Ñ´¡ Cardiol. 2016;1(1):73-79. doi:.
72.
Washam ÌýJB, Herzog ÌýCA, Beitelshees ÌýAL, Ìýet al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, Council on Functional Genomics and Translational Biology, Council on the Kidney in Cardiovascular Disease, and Council on Quality of Care and Outcomes Research. ÌýPharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association.ÌýÌý°ä¾±°ù³¦³Ü±ô²¹³Ù¾±´Ç²Ô. 2015;131(12):1123-1149.
73.
Mehta ÌýLS, Beckie ÌýTM, DeVon ÌýHA, Ìýet al; American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Cardiovascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. ÌýAcute myocardial infarction in women: a scientific statement from the American Heart Association.ÌýÌý°ä¾±°ù³¦³Ü±ô²¹³Ù¾±´Ç²Ô. 2016;133(9):916-947.
74.
Levine ÌýGN, Bates ÌýER, Bittl ÌýJA, Ìýet al; Focused Update Writing Group. Ìý2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published online March 23, 2016].ÌýÌýJ Am Coll Cardiol.
75.
Mozaffarian ÌýD, Benjamin ÌýEJ, Go ÌýAS, Ìýet al; Writing Group Members, American Heart Association Statistics Committee, Stroke Statistics Subcommittee. ÌýHeart disease and stroke statistics: 2016 update: a report from the American Heart Association.ÌýÌý°ä¾±°ù³¦³Ü±ô²¹³Ù¾±´Ç²Ô. 2016;133(4):e38-e60. doi:.
76.
Braunwald ÌýE, Kloner ÌýRA. ÌýMyocardial reperfusion: a double-edged sword?ÌýÌýJ Clin Invest. 1985;76(5):1713-1719.
77.
Hausenloy ÌýDJ, Botker ÌýHE, Engstrom ÌýT, Ìýet al. ÌýTargeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations [published online April 26, 2016].ÌýÌýEur Heart J.
78.
Everett ÌýBM, Pradhan ÌýAD, Solomon ÌýDH, Ìýet al. ÌýRationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.ÌýÌýAm Heart J. 2013;166(2):199-207.e15. doi:.
79.
Ridker ÌýPM, Thuren ÌýT, Zalewski ÌýA, Libby ÌýP. ÌýInterleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).ÌýÌýAm Heart J. 2011;162(4):597-605.
80.
Stone ÌýGW, Maehara ÌýA, Lansky ÌýAJ, Ìýet al; PROSPECT Investigators. ÌýA prospective natural-history study of coronary atherosclerosis [published correction appears in N Engl J Med. 2011;365(21):2040].ÌýÌýN Engl J Med. 2011;364(3):226-235.
81.
Kraemer ÌýS, Vaught ÌýJD, Bock ÌýC, Ìýet al. ÌýFrom SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay.ÌýÌýPLoS One. 2011;6(10):e26332. doi:.
82.
Bagai ÌýA, Al-Khalidi ÌýHR, Sherwood ÌýMW, Ìýet al. ÌýRegional Systems of Care Demonstration Project: Mission: Lifeline STEMI Systems Accelerator: design and methodology.ÌýÌýAm Heart J. 2014;167(1):15-21.e3. doi:.
Views 14,650
Review
³§±ð±è³Ù±ð³¾²ú±ð°ùÌý2016

Updates on Acute Coronary Syndrome: A Review

Author Affiliations
  • 1Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 2Department of Medicine, Harvard Medical School, Boston, Massachusetts
JAMA Cardiol. 2016;1(6):718-730. doi:10.1001/jamacardio.2016.2049
Abstract

ImportanceÌý Acute coronary syndrome (ACS), the acute manifestation of ischemic heart disease, remains a major cause of morbidity and mortality worldwide and is responsible for more than 1 million hospital admissions in the United States annually. Considerable research is being conducted in the field. This review provides a contemporary overview of key new findings on the pathophysiology, diagnosis, treatment, and prognosis of ACS.

ObservationsÌý While plaque rupture is the most frequent cause of coronary thrombosis, studies with optical coherence tomography demonstrate that superficial plaque erosion is more common than previously thought. High-sensitivity troponin assays (not yet available in the United States) and cardiac computed tomographic angiography are being increasingly used in diagnosis and risk stratification of patients with suspected ACS. New data from long-term dual antiplatelet therapy studies and investigations of anticoagulants provide important insights into the balance between ischemic and bleeding risks. The added benefit of percutaneous coronary intervention in non–infarct-related arteries in patients with ST-segment elevation myocardial infarction has been demonstrated in randomized trials, and the radial approach has become the standard of care in patients with ACS undergoing angiography. Promising old and new adjunctive therapies, such as pretreatment with β-blockers, ezetimibe, and proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, are discussed. New guidelines on the management of non–ST-segment elevation ACS were published in the last 2 years, as well as scientific documents on ACS in understudied populations, such as women and patients with renal dysfunction.

Conclusions and RelevanceÌý Substantial progress in the prevention, diagnosis, and management of patients with ACS has been accomplished in recent years. Despite optimal pharmacological and invasive therapies, the burden of recurrent ischemic events and mortality remains high, and future research is ongoing to prevent and improve the outcome of patients with ACS.

×